CE Mark Approval and Capital Raise Support European Expansion Strategy
4DMedical (ASX: 4DX) has achieved a major regulatory and funding milestone, receiving CE Mark certification for its CT: VQ™ technology while simultaneously completing a AU$83 million capital raise to support expansion into Europe.
The CE Mark approval enables commercial rollout of its non-contrast, CT-based ventilation-perfusion imaging solution across the European Union, opening access to a large and established respiratory imaging market. The rollout follows earlier implementations at leading academic medical institutions in the U.S.
The capital raise, completed at AU$5.90 per share, attracted strong institutional interest and provides funding to accelerate the European launch while maintaining a solid balance sheet. The pricing reflects a modest discount to the last close but a premium to recent trading averages.
Post-raising, the company maintains a strong cash position, supporting its growth strategy and international expansion plans.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
CE Mark Approval and Capital Raise Support European Expansion Strategy
4DMedical (ASX: 4DX) has achieved a major regulatory and funding milestone, receiving CE Mark certification for its CT: VQ™ technology while simultaneously completing a AU$83 million capital raise to support expansion into Europe.
The CE Mark approval enables commercial rollout of its non-contrast, CT-based ventilation-perfusion imaging solution across the European Union, opening access to a large and established respiratory imaging market. The rollout follows earlier implementations at leading academic medical institutions in the U.S.
The capital raise, completed at AU$5.90 per share, attracted strong institutional interest and provides funding to accelerate the European launch while maintaining a solid balance sheet. The pricing reflects a modest discount to the last close but a premium to recent trading averages.
Post-raising, the company maintains a strong cash position, supporting its growth strategy and international expansion plans.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au